Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
AssigneeThomas Jefferson University
InventorJay S. Schneider
Life of this patent
Estimating the term…
Abstract
The present invention involves the use of partial glycine agonists directed at the glycine modulatory site of the NMDA receptor to treat cognitive dysfunction in mammals with Parkinson's disease or schizophrenia.
Claims7
A method of treating cognitive dysfunction in mammals having Parkinson's disease, comprising administering a therapeutically effective amount of a partial glycine agonist to the glycine modulatory site of the NMDA receptor complex of said mammals, wherein said cognitive dysfunction is inattention.
A method of treating cognitive dysfunction and motor dysfunction in mammals having Parkinson's disease, comprising administering a therapeutically effective amount of a partial glycine agonist to the glycine modulatory site of the NMDA receptor complex of said mammals in combination with at least one of levodopa/carbidopa and/or a dopamine agonist, wherein said cognitive dysfunction is inattention.
A method of enhancing attention in a mammal comprising administering a partial glycine agonist to the glycine modulatory site of the NMDA receptor complex of said mammal.
Dependencies are inferred from the claim text.